Zenith Epigenetics Corp. announced that it has appointed Julie Cherrington PhD to act as the President and Chief Executive Officer. Julie has an extensive background leading companies focused on the discovery and development of novel cancer therapeutics and is well-versed in the challenges of developing drugs and advancing them into the clinic and through to commercialization.

Her accomplished employment record includes past notable positions such as CEO of Pathway Therapeutics Inc., President of Phenomix Corporation, Vice President, Preclinical Research and Exploratory Development SUGEN/Pharmacia/Pfizer, and Director, Virology at Gilead Sciences. Donald J. McCaffrey, founding CEO, will assume the title of Chairman and Dr. Peter Johann will act as Lead Director.